Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28399911)

  • 1. The role of c-Myc-RBM38 loop in the growth suppression in breast cancer.
    Li XX; Shi L; Zhou XJ; Wu J; Xia TS; Zhou WB; Sun X; Zhu L; Wei JF; Ding Q
    J Exp Clin Cancer Res; 2017 Apr; 36(1):49. PubMed ID: 28399911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer.
    Zhou XJ; Wu J; Shi L; Li XX; Zhu L; Sun X; Qian JY; Wang Y; Wei JF; Ding Q
    J Exp Clin Cancer Res; 2017 Oct; 36(1):149. PubMed ID: 29052531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RBM38 is involved in TGF-β-induced epithelial-to-mesenchymal transition by stabilising zonula occludens-1 mRNA in breast cancer.
    Wu J; Zhou XJ; Sun X; Xia TS; Li XX; Shi L; Zhu L; Zhou WB; Wei JF; Ding Q
    Br J Cancer; 2017 Aug; 117(5):675-684. PubMed ID: 28683467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
    Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
    J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
    Zhang M; Xu E; Zhang J; Chen X
    Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
    Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
    Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-binding protein RBM38 inhibits colorectal cancer progression by partly and competitively binding to PTEN 3'UTR with miR-92a-3p.
    Guan B; Li G; Wan B; Guo X; Huang D; Ma J; Gong P; Guo J; Bu Y
    Environ Toxicol; 2021 Dec; 36(12):2436-2447. PubMed ID: 34453780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer.
    Shen H; Zhao L; Feng X; Xu C; Li C; Niu Y
    Oncotarget; 2016 Sep; 7(37):60407-60418. PubMed ID: 27494865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.
    Feldstein O; Ben-Hamo R; Bashari D; Efroni S; Ginsberg D
    Mol Cancer Res; 2012 Sep; 10(9):1169-77. PubMed ID: 22798430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
    Cosgrave N; Hill AD; Young LS
    J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.
    Kong LM; Liao CG; Zhang Y; Xu J; Li Y; Huang W; Zhang Y; Bian H; Chen ZN
    Cancer Res; 2014 Jul; 74(14):3764-78. PubMed ID: 24906624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein.
    Xiong J; Du Q; Liang Z
    Oncogene; 2010 Sep; 29(35):4980-8. PubMed ID: 20562918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel AU-Rich element in the 3' untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins.
    Balmer LA; Beveridge DJ; Jazayeri JA; Thomson AM; Walker CE; Leedman PJ
    Mol Cell Biol; 2001 Mar; 21(6):2070-84. PubMed ID: 11238942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RBMS2 inhibits the proliferation by stabilizing P21 mRNA in breast cancer.
    Sun X; Hu Y; Wu J; Shi L; Zhu L; Xi PW; Wei JF; Ding Q
    J Exp Clin Cancer Res; 2018 Dec; 37(1):298. PubMed ID: 30514345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc.
    Pawar SA; Szentirmay MN; Hermeking H; Sawadogo M
    Oncogene; 2004 Aug; 23(36):6125-35. PubMed ID: 15208653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC Increases
    Abdullah C; Korkaya H; Iizuka S; Courtneidge SA
    Mol Cell Biol; 2018 Mar; 38(6):. PubMed ID: 29263157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer.
    Lou P; Li C; Shi L; Xia TS; Zhou W; Wu J; Zhou X; Li X; Wang Y; Wei JF; Ding Q
    Oncotarget; 2017 Mar; 8(10):16387-16400. PubMed ID: 27634883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.
    Barsyte-Lovejoy D; Lau SK; Boutros PC; Khosravi F; Jurisica I; Andrulis IL; Tsao MS; Penn LZ
    Cancer Res; 2006 May; 66(10):5330-7. PubMed ID: 16707459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of RNA-binding protein RBM38 decreased in renal cell carcinoma and represses renal cancer cell proliferation, migration, and invasion.
    Huang W; Wei XL; Ni W; Cao M; Meng L; Yang H
    Tumour Biol; 2017 May; 39(5):1010428317701635. PubMed ID: 28459215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.
    Gao X; Liu X; Lu Y; Wang Y; Cao W; Liu X; Hu H; Wang H
    Breast Cancer; 2019 Sep; 26(5):663-671. PubMed ID: 30989585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.